Cell-penetrating peptide and conjugate comprising same
A cell-penetrating peptide, a conjugate of the cell-penetrating peptide with an anticancer agent, and a composition comprising the conjugate is described. An effective means for transferring a cancer-specific anticancer agent can be provided by using the cell-penetrating peptide. More particularly, by preparing the conjugate of the present invention wherein the cell-penetrating peptide and the anticancer agent are combined, the application concentration of a conventional anticancer agent can be reduced and cancer specificity can be provided, and thus an effect of reducing side effects during the treatment process can be obtained.
1. A cell penetrating carrier peptide, wherein the carrier peptide is 20 amino acids in length and consists of the amino acid sequence of SEQ ID NO: 1.
2. A cell penetrating carrier peptide, wherein the carrier peptide is 20 amino acids in length and consists of a thiol-modified amino acid sequence of SEQ ID NO: 1.
3. The cell penetrating peptide of claim 2 , wherein the thiol-modification is a mercaptoacetyl-aminohexanoic acid modification.
4. A pharmaceutical composition comprising a cell penetrating carrier peptide and an active ingredient, wherein the carrier peptide consists of the amino acid sequence of SEQ ID NO: 1.
5. The pharmaceutical composition of claim 4 , wherein the active ingredient is selected from the group consisting of: proteins, nucleic acids, peptides, lipids, glycol-lipids, minerals, sugars, nano-particles, contrast agents, drugs, and chemical compounds.
6. The pharmaceutical composition of claim 5 , wherein the active ingredient is selected from the group consisting of cytokines, antibodies, fragments of antibodies, therapeutic enzymes, soluble receptors and ligands.
7. The pharmaceutical composition of claim 4 , wherein the active ingredient is an anti-cancer agent.
8. The pharmaceutical composition of claim 7 , wherein the anti-cancer agent is a taxane or a STAT3 inhibitor.
9. The pharmaceutical composition of claim 8 , wherein the tamale is paclitaxel.
10. The pharmaceutical composition of claim 8 , wherein the STAT3 inhibitor is NSC74859.
11. The pharmaceutical composition of claim 4 , wherein the pharmaceutical composition has cell penetrability for delivery of the active ingredient into a cell.
12. The pharmaceutical composition of claim 4 , further comprising an additive selected from the group consisting of excipients, lubricants, binders, disintegrants, buffers, dispersants, surfactants, coloring agents, aromatics, and sweeteners.